Initial results with [<sup>18</sup>F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 38117298.
- Also identified by DOI 10.1007/s00259-023-06564-y and PMC identifier 11043111.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. <sup>68</sup>Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, <sup>18</sup>F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [<sup>18</sup>F]FAPI-74 prospectively in a small patient cohort. Eight patients underwent both [<sup>18</sup>F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. The initial results confirm our assumption that [<sup>18</sup>F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.
Medical subject headings
- Idiopathic Pulmonary Fibrosis
- Positron Emission Tomography Computed Tomography